Cite
HARVARD Citation
Suri, A. et al. (2019). Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study. Clinical pharmacology & therapeutics. 106 (6), pp. 1268-1279. [Online].